Other Events ·
Rafael Holdings completes final patient visit in pivotal Phase 3 study for Trappsol Cyclo; topline data expected H1 2026
RFLRafael Holdings, Inc.
Rafael Holdings, Inc. announced that the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C. Topline data from the main study cohort is expected to be announced in the second half of 2026. Rafael Holdings, Inc. is a biotechnology company focused on developing therapeutic treatments for rare diseases.